Clinical trials: Disease Exacerbation
Pulmonary Disease, Chronic Obstructive
Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in European Symptomatic Subjects From Primary Care
This is a prospective, observational, non-drug interventional, non-randomized study to compare the rate of moderate-severe COPD exacerbations in patients of all Chronic Obstructive Pulmonary Disease (COPD) severities with and…
- Trial name
- ACCESS (NCT01516528)
- Testing
- Spirometry
- Where
- 233 sites in Belgium, France and 4 more
- Volunteers
- 3,500 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive Patients Admitted in Emergency Department for Acute Exacerbation
Prognosis Value of Pro-adrenomedullin in Acute Exacerbations of COPD in ER
The purpose of this study is to determine whether pro-adrenomedullin (Mr proADM)in addition to clinical evaluation is effective to predict outcome of acute exacerbations of COPD patients visiting the emergency room(ER).
- Trial name
- UTAPE BPCO (NCT01857947)
- Testing
- AECOPD Mr proADM
- Where
- 2 sites in France
- Volunteers
- 370 people
- Sponsor
- ThermoFisher Scientific Brahms Biomarkers France
Seborrheic Dermatitis
Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation
The goal of this research is to demonstrate the use of petroleum jelly in prevention of nonscalp seborrheic dermatitis exacerbations at the first signs of a flare.
- Trial name
- NCT01315951
- Testing
- Petroleum Jelly
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Ascension Health
Schizophrenia
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.
- Trial name
- NCT00254202
- Testing
- Iloperidone, Ziprasidone
- Where
- 42 sites in United States, India
- Volunteers
- 593 people
- Sponsor
- Vanda Pharmaceuticals
Chronic Obstructive Pulmonary Disease
A Study of the Inflammatory Pathways Associated With Chronic Obstructive Pulmonary Disease Exacerbations
The purpose of this study is to observe how the inflammatory pathways differ in subjects with chronic obstructive pulmonary disease (COPD) during an acute exacerbation of COPD (AECOPD).
- Trial name
- NCT01337661
- Where
- Ireland
- Volunteers
- 26 people
- Sponsor
- MedImmune LLC
Schizophrenia, Schizoaffective Disorder
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
This study will investigate the efficacy and safety of RO6889450 as monotherapy in participants experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder.
- Trial name
- NCT04512066
- Testing
- RO6889450, Risperidone
- Where
- 40 sites in United States, Japan and 2 more
- Volunteers
- 287 people
- Sponsor
- Hoffmann-La Roche
Bronchitis, Chronic Bronchitis
A Study of the Effectiveness and Safety of High Dose, Short-course Levofloxacin in the Treatment of Acute Bacterial Exacerbation (Worsening) of Chronic Bronchitis.
The purpose of this study is to evaluate the safety and effectiveness of four oral antibiotic treatment regimens for bacterial infections in patients with chronic bronchitis.
- Trial name
- NCT00042718
- Testing
- levofloxacin, azithromycin, amoxicillin/clavulanate
- Volunteers
- 659 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Pulmonary Disease, Chronic Obstructive
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2
A randomized, placebo-controlled, double-blind, parallel group, multi-center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD)…
- Trial name
- NCT01662986
- Testing
- tiotropium bromide
- Where
- 50 sites in United States
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia
Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia
The objective of this study is demonstrate efficacy and a dose-response in the treatment of acute exacerbation of schizophrenia in comparison to placebo.
- Trial name
- NCT00580125
- Testing
- PF-00217830, Aripiprazole
- Where
- 26 sites in United States, India and 2 more
- Volunteers
- 164 people
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive
Research to Evaluate a Possible Relation Between Values Obtained After Processing CT Images, Lung Function Tests and the Experience of the Patient During an Exacerbation in COPD Patients.
In this study the consequences of exacerbations will be visualized by high resolution computed tomography (HRCT) scan at functional residual capacity (FRC) and total lung capacity (TLC) as taken during an episode of exacerbation…
- Trial name
- NCT01684384
- Testing
- Functional Respiratory Imaging
- Where
- 4 sites in Belgium, Italy and 1 more
- Volunteers
- 53 people
- Sponsor
- FLUIDDA nv
Schizophrenia
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
The purpose of this study is to evaluate the efficacy, safety and tolerability of TAK-063 compared with placebo in treatment of acutely exacerbated schizophrenia.
- Trial name
- NCT02477020
- Testing
- TAK-063 20 mg
- Where
- 15 sites in United States
- Volunteers
- 164 people
- Sponsor
- Takeda
Asthma
Prevention of Asthma Relapse After Discharge From Emergency
The purpose of this study is to compare the Symbicort® Turbuhaler® to both Pulmicort® Turbuhaler® and Bricanyl® Turbuhaler® for the treatment of asthma after discharge from the emergency room
- Trial name
- PARADE (NCT00326053)
- Testing
- Budesonide/formoterol
- Where
- 20 sites in Canada
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Asthma
Exacerbation Risk in Asthma
The purpose of this study is to conduct a comparative analysis of patients using Tiotropium in combination with Inhaled Corticosteroids (ICS) versus those that use long-acting β2-agonists (LABA) medication in combination with ICS.
- Trial name
- NCT05501639
- Testing
- tiotropium, long-acting β2-agonists (LABA), inhaled corticosteroids (ICS)
- Where
- United States
- Volunteers
- 1,899 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
COPD is a condition which affects over 3 million people in the UK. It causes chronic symptoms including breathlessness and cough, limitations in exercise tolerance and acute exacerbations of COPD (AECOPD) which often lead to…
- Trial name
- PROPEL myCOPD (NCT05835492)
- Testing
- myCOPD
- Where
- 3 sites in United Kingdom
- Volunteers
- 200 people
- Sponsor
- my mhealth Ltd
Chronic Obstructive Pulmonary Diseases
Trial of E-Health Platform Supported Care vs Usual Care After Exacerbation of COPD
There are currently 900,000 people in the UK with a diagnosis of Chronic Obstructive Pulmonary Disease (COPD), The disease is progressive and often causes disabling symptoms such as chronic cough, breathlessness and reduced…
- Trial name
- RESCUE (NCT02706600)
- Testing
- myCOPD, Written Self management plan
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- my mhealth Ltd
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies
- Trial name
- GALATHEA (NCT02138916)
- Testing
- Benralizumab Arm A, Benralizumab Arm B
- Where
- 407 sites in United States, Austria and 15 more
- Volunteers
- 1,656 people
- Sponsor
- AstraZeneca
Asthma
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically…
- Trial name
- NIMBLE (NCT04718389)
- Testing
- GSK3511294 (Depemokimab), Mepolizumab, Benralizumab
- Where
- 397 sites in United States, Australia and 19 more
- Volunteers
- 1,717 people
- Sponsor
- GlaxoSmithKline
Comparative Effectiveness Study
Treatment and Exacerbation in COPD Subjects
This is a study comparing the effects of ICS containing treatments in patients with chronic obstructive pulmonary disease (COPD) in a real world setting, using the UK Clinical Practice Research Datalink (CPRD) linked with…
- Trial name
- NCT03375450
- Testing
- Standard of Care
- Where
- United Kingdom
- Volunteers
- 60,243 people
- Sponsor
- AstraZeneca
COPD
Loop Band Validation Study
The main purpose of this study is to assess the accuracy of a non-invasive wearable technology in the form of a wristband.
- Trial name
- NCT03240926
- Testing
- Loop Band
- Where
- United States
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- Spry Health
Bronchitis, Chronic
A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Cefuroxime Axetil in the Treatment of Adults With Persistent Bronchitis Experiencing Rapid Onset of Severe Worsening of Symptoms Caused by Bacteria
The purpose of this study is to evaluate the safety and effectiveness of levofloxacin, an antibiotic, compared with cefuroxime axetil, another antibiotic, in the treatment of adults with chronic bronchitis experiencing rapid…
- Trial name
- NCT00269932
- Testing
- levofloxacin
- Volunteers
- 485 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.